Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern - Lasagna, A.; Bergami, F.; Lilleri, D.; Percivalle, E.; Quaccini, M.; Serra, F.; Comolli, G.; Sarasini, A.; Sammartino, J.C.; Ferrari, A.; Arena, F.; Secondino, S.; et al. (ESMO open, 2022)
Keywords: Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; COVID-19 - prevention & control; COVID-19 Vaccines - pharmacology; Humans; Immunity, Cellular; Immunoglobulin G; Longitudinal Studies; mRNA Vaccines; Neoplasms - drug therapy; neutralizing antibody; Original Research; Oxygen; SARS-CoV-2; third dose; Viral Vaccines - genetics; VOCs; VOCs; neutralizing antibody; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; third dose